Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alzamend Neuro (NASDAQ: ALZN ) stock is on the move Thursday after getting an update from the U.S. Food and Drug Administration (FDA). Source: Shutterstock The FDA sent a letter to Alzamend Neuro detailing t...
Gainers: Alzamend Neuro (NASDAQ:ALZN) +52%, Progenity (NASDAQ:PROG) +18%, OptimizeRx (NASDAQ:OPRX) +15%, Atea Pharmaceuticals (NASDAQ:AVIR) +14%, Perrigo (NYSE:PRGO) +11%. Losers: Corvus Pharmaceuticals (NASDAQ:CRVS) -15%, NuCana (NASDAQ:NCNA)...
FDA Agrees to Alzamend’s Plan to Conduct a Combined Phase 1 and 2 Clinical Trial for AL002 Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of...
Company Achieves Milestone of Dosing First Group of Participants in Six-Month Comparative Study with Lithium-Delivering Ionic Cocrystal Oral Treatment Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company ...
You can read full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Investors will get a test next week when the consumer report index report drops on September 15 to give a read on inflat...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that it contracted Altasciences to ...
Ault Global Holdings' (NYSE:DPW) wholly owned subsidiary, Digital Power Lending (DPL) has made an additional investment in Alzamend Neuro (NASDAQ:ALZN). ALZN shares up 4.7% premarket at $4.50. On July 28, 2021, Alzamend received a “study may proceed” letter from the FD...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”) announced that Digital Power Lending, LLC (“ DPL ”), a wholly owned subsidiary of Ault Global Holdings, Inc. (“ AGH ”) (NYSE American: DPW), a diversified holding company...
Alzamend Neuro (NASDAQ:ALZN) perks up 2.8% premarket after submitting a pre-IND meeting request for AL002 and supporting briefing documents to FDA's Center for Biological Evaluation and Research. AL002 is a patented method using a mutant-peptide sensitized cell as a cell-based ...
News, Short Squeeze, Breakout and More Instantly...
AstraZeneca PLC (AZN) is expected to report $0.97 for Q2 2024 BJ's Restaurants Inc. (BJRI) is expected to report $0.49 for Q2 2024 Baker Hughes Company (BKR) is expected to report $0.49 for Q2 2024 BlueHarbor Bank (BLHK) is expected to report for Q2 2024 Betterware de Mexico S.A.P...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major de...
Investor had agreed to purchase up to $25 million of preferred shares Alzamend expects to use proceeds to further its clinical trials and working capital purposes Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical compa...